Background and Relevance
In early 2025, the Mexican government decided to cancel a highly anticipated large-scale public procurement of medicines and healthcare supplies for the six-year term. Despite this, the promised supply in public hospitals remains unfulfilled. Over 2025, numerous public acquisition processes in the healthcare sector have fallen short due to opaque and poorly understood procedures, failing to resolve chronic shortages.
The Case: Birmex’s 2026 Medicine and Healthcare Supplies Purchase
Jorge Javier Jiménez Alcaraz, an independent social witness, has raised concerns about potential unfair practices in Birmex’s recent international open electronic public tender (LA-12-NEF-012NEF001-I-59-2025) to procure medicines, therapeutic goods, and healthcare supplies for 2026. This purchase aims to supply ISSSTE, IMSS, IMSS-Bienestar, and Pemex. Jiménez Alcaraz’s testimony, submitted to the Secretaría de la Función Pública (SFP) under Raquel Buenrostro, highlights suspicious pricing patterns that warrant investigation.
The Tender Process
Birmex published the tender’s call in October, intending to acquire 280 medical supply keys to consolidate demand from the mentioned institutions and secure better prices and conditions. The process, governed by the Ley de Adquisiciones, Arrendamientos y Servicios del Sector Público (LAASSP), includes stages like clarifying meetings, proposal submissions, and a bidding act on October 3, 2025.
Social Witness Testimony
Jiménez Alcaraz’s 68-page testimony praises the use of subsequent discount offers to foster competition. However, it highlights a significant concern: suspiciously low, non-sustainable prices among the selected suppliers, potentially indicating “dumping” practices. A clear example is the key 010.000.6259.00, corresponding to Labetalol injectable solution (100 mg/20 ml), used in cardiology for hypertension and cardiac emergencies.
Suspicious Offers
The offers for this key show signs of irregularity. The demanded quantity ranges from 26,616 to 66,526 units, while the unit price fluctuates between $500 and $3,500 pesos. The evaluation criterion is simply “complies” or “does not comply.” Here are the details of the proposals:
- MAYANFARMA, S.A. DE C.V.: $439.00 per unit (minimum: $11,684,424.00; maximum: $29,204,914.00).
- MARELAB FARMA, S.A. DE C.V.: $497.34 (minimum: $13,237,201.44; maximum: $33,086,040.84), manufactured by Caplin Steriles Limited (India).
- RIMISA MEDICAL, S.A. DE C.V.: $518.73 (minimum: $13,806,517.68; maximum: $34,509,031.98), by Candi Pharma, Ltd.
- NATURMEDIQUIM, S.A. DE C.V.: $3,553.00 (minimum: $94,666,046.00; maximum: $235,336,976.00), by Neim Pharma, S.L. (Spain).
The lowest offer, from MayanFarma, is eight times lower than the highest, suggesting prices below production costs. Birmex failed to provide the requested market research (TS/BIRMEX/002/2025, August 7; TS/BIRMEX/031/2025, September 30), violating LAASSP Article 67, which mandates transparency through documentation.
Implications and Recommendations
Without market research, it’s impossible to assess the economic viability or dismiss anomalously low offers. Birmex sent international trade regulations (TS/BIRMEX/030/2025) to ensure foreign suppliers’ feasibility and prevent supply shortage risks. This case reflects ongoing challenges in consolidated purchases, where immediate cost savings can overlook long-term sustainability.
If dumping is confirmed, the adjudications could be invalidated, and Birmex may face penalties. The testimony has been submitted to the SFP; we hope for a thorough investigation, including audits of offers and involved manufacturers.
Birmex must take its role as a professional healthcare purchaser more seriously, conduct timely requirement forecasts, and provide comprehensive market research to encourage genuine participation and competition. Transparency is non-negotiable in the medical sector, crucial for ethical business prioritizing public health over short-term gains.
Key Questions and Answers
- What is the concern in Birmex’s 2026 medicine and healthcare supplies purchase?
The concern is potential unfair practices, specifically suspiciously low, non-sustainable prices among selected suppliers, which may indicate “dumping” practices.
- What is the role of the social witness, Jorge Javier Jiménez Alcaraz?
Jiménez Alcaraz, an independent social witness, raised concerns about these potential unfair practices in Birmex’s tender process and submitted his testimony to the Secretaría de la Función Pública (SFP).
- Why is market research crucial in this case?
Without market research, it’s impossible to assess the economic viability of offers or dismiss anomalously low ones, ensuring transparency and fair competition.
- What are the potential consequences if dumping is confirmed?
If dumping is confirmed, the adjudications could be invalidated, and Birmex may face penalties.
